FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022460159> ?p ?o ?g. }

• W3022460159 abstract "Abstract Introduction: Immune checkpoint blockade has revealed a remarkable success in the treatment of a range of cancer types. Immune-related adverse events on the endocrine system may be permanent and carry high morbidity and mortality. Case: A 35-year-old black male presented to the ED with acute onset diffuse abdominal pain, along with nausea and vomiting. Review of systems was positive for polyuria and polydipsia. The examination was unremarkable apart from a sizeable fungating lesion of the left lower extremity by the ankle measuring 12 x 8 cm. Investigations indicated blood sugars around 600, serum bicarbonate of 19 mEq/L, an anion gap of 19 mEq/L, serum BHB was elevated, and lactate within normal. The patient was diagnosed with DKA, started on an insulin drip, and admitted to the ICU. Our patient had no known personal or family history of diabetes. A few years ago, he had suffered from a non-healing chronic ulcer in his left ankle secondary to a motor vehicle accident. Three months ago, he had been diagnosed with a well-differentiated squamous cell carcinoma, arising from his chronic non-healing ulcer. One month ago, He had started Pembrolizumab 200mg Intravenously, and he had received a total of two cycles, the last cycle was one week ago. Shortly after he presented to the ED with the above chief complaint. He made a complete recovery and further investigations revealed HbA1c of 7.2%, C-peptide levels of &lt;0.1 ng/mL, which supports the diagnosis of T1-DM. He was discharged home, and Pembrolizumab was continued. Conclusion: Autoimmune T1-DM has been reported after receiving anti-PD-1 therapy. In a recent study included 27 patients with a variety of solid-organ cancers, and all had received anti–PD-1 antibodies treatment, autoimmune, T1-DM diabetes occurred in close to 1% of patients (1). A systematic review and meta-analysis were conducted recently showed that people developed T1-DM within three months of the initial PD-1 inhibitor exposure. Since patients treated with anti–PD-1 antibodies can present with life-threatening DKA, a high index of suspicion is crucial as early detection is the key to successful treatment and prevention of morbidity and mortality. It remains unclear if it is safe to restart the checkpoint inhibitor after an immune-related adverse event, and further studies are necessary in order to resolve this dilemma. A recent retrospective study included patients with melanoma showed that anti–PD-1 therapy could be safely resumed after severe adverse event requiring immunosuppression (2). References: 1. Stamatouli, A. M. et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 67, 1471–1480 (2018). 2. Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017)." @default.
• W3022460159 created "2020-05-13" @default.
• W3022460159 creator A5028207650 @default.
• W3022460159 creator A5032537689 @default.
• W3022460159 creator A5045726343 @default.
• W3022460159 creator A5055585097 @default.
• W3022460159 date "2020-04-01" @default.
• W3022460159 modified "2023-10-17" @default.
• W3022460159 title "SAT-680 Diabetes Mellitus Induced by Programmed Cell Death-1 (PD-1) Inhibitors: A Case Report" @default.
• W3022460159 doi "https://doi.org/10.1210/jendso/bvaa046.009" @default.
• W3022460159 hasPublicationYear "2020" @default.
• W3022460159 type Work @default.
• W3022460159 sameAs 3022460159 @default.
• W3022460159 citedByCount "0" @default.
• W3022460159 crossrefType "journal-article" @default.
• W3022460159 hasAuthorship W3022460159A5028207650 @default.
• W3022460159 hasAuthorship W3022460159A5032537689 @default.
• W3022460159 hasAuthorship W3022460159A5045726343 @default.
• W3022460159 hasAuthorship W3022460159A5055585097 @default.
• W3022460159 hasBestOaLocation W30224601591 @default.
• W3022460159 hasConcept C126322002 @default.
• W3022460159 hasConcept C134018914 @default.
• W3022460159 hasConcept C141071460 @default.
• W3022460159 hasConcept C2779624480 @default.
• W3022460159 hasConcept C2780180277 @default.
• W3022460159 hasConcept C2780580376 @default.
• W3022460159 hasConcept C2780852908 @default.
• W3022460159 hasConcept C2780955771 @default.
• W3022460159 hasConcept C555293320 @default.
• W3022460159 hasConcept C71924100 @default.
• W3022460159 hasConcept C90924648 @default.
• W3022460159 hasConceptScore W3022460159C126322002 @default.
• W3022460159 hasConceptScore W3022460159C134018914 @default.
• W3022460159 hasConceptScore W3022460159C141071460 @default.
• W3022460159 hasConceptScore W3022460159C2779624480 @default.
• W3022460159 hasConceptScore W3022460159C2780180277 @default.
• W3022460159 hasConceptScore W3022460159C2780580376 @default.
• W3022460159 hasConceptScore W3022460159C2780852908 @default.
• W3022460159 hasConceptScore W3022460159C2780955771 @default.
• W3022460159 hasConceptScore W3022460159C555293320 @default.
• W3022460159 hasConceptScore W3022460159C71924100 @default.
• W3022460159 hasConceptScore W3022460159C90924648 @default.
• W3022460159 hasLocation W30224601591 @default.
• W3022460159 hasLocation W30224601592 @default.
• W3022460159 hasOpenAccess W3022460159 @default.
• W3022460159 hasPrimaryLocation W30224601591 @default.
• W3022460159 hasRelatedWork W12070973 @default.
• W3022460159 hasRelatedWork W1261559 @default.
• W3022460159 hasRelatedWork W1537852 @default.
• W3022460159 hasRelatedWork W2390609 @default.
• W3022460159 hasRelatedWork W3156605 @default.
• W3022460159 hasRelatedWork W4442955 @default.
• W3022460159 hasRelatedWork W4640920 @default.
• W3022460159 hasRelatedWork W7936300 @default.
• W3022460159 hasRelatedWork W9560361 @default.
• W3022460159 hasRelatedWork W18389659 @default.
• W3022460159 isParatext "false" @default.
• W3022460159 isRetracted "false" @default.
• W3022460159 magId "3022460159" @default.
• W3022460159 workType "article" @default.